162 related articles for article (PubMed ID: 32847837)
1. Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects.
Moscetti L; Hennik P; Bolstad B; Camarero J; Josephson F; Melchiorri D; Sommerfelt Grønvold M; Sjoberg J; Botezatu M; Mulder J; Meulendijks D; Trullas Jimeno A; Zafiropoulos N; Bergh J; Enzmann H; Pignatti F
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847837
[TBL] [Abstract][Full Text] [Related]
2. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
3. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
4. Real world treatment sequences and outcomes for metastatic renal cell carcinoma.
Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
PLoS One; 2023; 18(11):e0294039. PubMed ID: 37992086
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Chen X; Xu Z; Wu C; Xie L; Wang P; Liu X
Front Immunol; 2024; 15():1255577. PubMed ID: 38390328
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
[No Abstract] [Full Text] [Related]
8. A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma.
Shay R; Nicklawsky A; Gao D; Lam ET
Clin Genitourin Cancer; 2021 Aug; 19(4):370-370.e7. PubMed ID: 33674224
[TBL] [Abstract][Full Text] [Related]
9. Developments in personalized therapy for metastatic renal cell carcinoma.
Fujiwara R; Kageyama S; Yuasa T
Expert Rev Anticancer Ther; 2022 Jun; 22(6):647-655. PubMed ID: 35531636
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
Mason NT; Joshi VB; Adashek JJ; Kim Y; Shah SS; Schneider AM; Chadha J; Jim HSL; Byrne MM; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
Eur Urol Oncol; 2023 Jun; 6(3):331-338. PubMed ID: 36797084
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
Vitale MG; Nasso C; Oltrecolli M; Baldessari C; Fanelli M; Dominici M; Sabbatini R
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1183-1192. PubMed ID: 34424125
[TBL] [Abstract][Full Text] [Related]
12. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group.
Grünwald V; Bergmann L; Brehmer B; Eberhardt B; Kastrati K; Gauler T; Gehbauer G; Gschwend J; Johannsen M; Klotz T; Protzel C; Schenck M; Staehler M
World J Urol; 2022 Oct; 40(10):2381-2386. PubMed ID: 35562599
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date.
Chau V; Bilusic M
Cancer Manag Res; 2020; 12():7321-7330. PubMed ID: 32884346
[TBL] [Abstract][Full Text] [Related]
15. The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
Ha H; Kang JH; Kim DY; Bae SJ; Lee HY
BMC Health Serv Res; 2022 Jul; 22(1):900. PubMed ID: 35821026
[TBL] [Abstract][Full Text] [Related]
16. First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape.
Gulati S; Labaki C; Karachaliou GS; Choueiri TK; Zhang T
Oncologist; 2022 Mar; 27(2):125-134. PubMed ID: 35641205
[TBL] [Abstract][Full Text] [Related]
17. [Risk-adapted therapy for metastatic renal cell carcinoma].
Grimm MO; Leucht K; Foller S; Grünwald V
Urologe A; 2020 Feb; 59(2):155-161. PubMed ID: 32006060
[TBL] [Abstract][Full Text] [Related]
18. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.
Albiges L; Powles T; Staehler M; Bensalah K; Giles RH; Hora M; Kuczyk MA; Lam TB; Ljungberg B; Marconi L; Merseburger AS; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Bex A
Eur Urol; 2019 Aug; 76(2):151-156. PubMed ID: 31151678
[TBL] [Abstract][Full Text] [Related]
19. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M
Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206
[No Abstract] [Full Text] [Related]
[Next] [New Search]
